Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
report tags : Trial save search
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.89 1.03% 1.02% 250K
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
ICCM | $1.23 -4.03% 120K
|
Manufacturing
| Email alert
Add to watchlist
free breast cancer medical trial results
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
MRNS | $1.38 -2.13% -2.17% 2.6M
|
Health Technology
|
| O: -75.4%
H: 5.41%
C: -29.73%
first update pharmaceuticals trial financial results
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
Published: 2024-04-09 (Crawled : 22:00) - globenewswire.com
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: -2.59%
H: 1.75%
C: 0.25%
ongoing trial
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
KA A | $0.5196 6.89% 6.45% 480K
|
Manufacturing
|
| O: -12.68%
H: 3.59%
C: -8.72%
vista-101 ongoing trial response
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Published: 2024-04-02 (Crawled : 16:00) - biospace.com/
KRBP | $2.5 -90.21% 830
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.0%
favorable biopharma trial
Global $4.1 Billion Clinical Trial Supplies Market Report 2024-2034 - Emerging Markets Catalyzing Growth in Clinical Trial Supplies
Published: 2024-03-26 (Crawled : 17:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.43%
report global trial growth market
Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch
Published: 2024-03-25 (Crawled : 16:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 0.02%
H: 0.31%
C: -1.65%
INFY | $16.81 1.82% -1.31% 15M
|
Technology Services
|
| O: 0.4%
H: 0.0%
C: -0.9%
CTLT | $55.48 -0.57% -0.4% 1.6M
|
Health Technology
|
| O: 0.54%
H: 0.82%
C: 0.55%
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 0.02%
H: 0.34%
C: -0.68%
report reach trial market
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
Published: 2024-03-21 (Crawled : 10:00) - globenewswire.com
BNOX | $0.98 -1.17% 14K
|
n/a
|
| O: 2.75%
H: 3.74%
C: -6.54%
bnc210 trial results
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
KURA | $17.55 -0.74% -0.74% 1.3M
|
Health Technology
|
| O: 1.28%
H: 8.54%
C: 6.52%
ko-2806 first renal cell trial plus
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
Published: 2024-03-04 (Crawled : 21:00) - globenewswire.com
APGE | $46.98 -2.83% -2.92% 470K
|
|
| O: 43.53%
H: 9.18%
C: -1.02%
apg777 conference report antibody dermatitis treatment trial results
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
Published: 2024-02-21 (Crawled : 13:30) - neurosense.investorroom.com
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: -3.65%
H: 0.0%
C: -5.3%
als positive trial results
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
Published: 2024-02-21 (Crawled : 12:30) - prnewswire.com
KZIA | $0.379 9.47% 8.65% 300K
|
Health Technology
|
| O: 7.84%
H: 5.09%
C: -26.38%
trial therapeutics
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
Published: 2024-02-15 (Crawled : 22:00) - globenewswire.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: -15.23%
H: 6.88%
C: -0.9%
year update trial financial
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
Published: 2024-02-15 (Crawled : 13:00) - biospace.com/
NNVC | $1.1 -6.38% 0.0% 22K
|
Health Technology
|
| O: 2.56%
H: 0.83%
C: -0.83%
nv-387 covid report treatment trial
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 2.77%
H: 2.69%
C: 1.92%
cm04 covid-19 vaccine universal geo-cm04s1 positive trial
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.41%
H: 5.51%
C: 3.26%
pharma positive trial results study
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
Published: 2024-01-29 (Crawled : 15:00) - biospace.com/
KRBP | $2.5 -90.21% 830
|
Health Technology
|
| O: -6.67%
H: 27.14%
C: 26.43%
first lung favorable cancer cell biopharma trial results
Global Pharma Clinical Trial Services Market Report 2024: Harnessing AI and Real-World Data for Clinical Trial Innovation and Services - Long-term Forecast to 2034
Published: 2024-01-25 (Crawled : 17:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -1.03%
H: 0.84%
C: -0.92%
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
|
| O: 0.78%
H: 0.76%
C: 0.69%
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 0.76%
H: 0.71%
C: -0.09%
pharma services report innovation global trial market
NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Published: 2024-01-18 (Crawled : 13:00) - prnewswire.com
NRBO | $3.325 -3.34% -3.46% 21K
|
Health Technology
|
| O: 0.59%
H: 3.24%
C: 0.88%
da-1241 pre-clinical positive treatment pharmaceuticals trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.